Apollo Cancer Centres, part of group in exclusive partnership with Datar Cancer Genetics, on Wednesday announced the launch of a blood test that can detect breast cancers at early stages in asymptomatic individuals with high accuracy.
The test called EasyCheck- Breast can help in the detection of breast cancer even before the first stage by drawing a small sample of blood.
The EasyCheck- Breast test developed by Nashik-based molecular diagnostics company Datar Cancer Genetics, has received breakthrough designated status by USFDA and has been approved by the UK and Europe. The test is designed to detect breast adenocarcinoma specific cancer tumor cells in the blood.
In clinical trials – the EasyCheck- Breast was tested on 8112 asymptomatic women with baseline cancer risk and BIRADS-1 on mammography and 217 known breast cancer cases. The test came out with sensitivity of 88.2%, specificity and accuracy at 99%.
The test is recommended in consultation with a qualified physician for asymptomatic women of 40 years and above.
MORE STORIES FOR YOU✕
« Back to recommendation stories
The test will cost about Rs 6000.
The test will be an addition to the existing self-breast examination, clinical breast examination, mammogram and ultrasound that are available in the market.
“In line with our mission to spread awareness about early detection of cancers and offer world-class cancer treatment, the launch of EasyCheck Breast marks an important success towards quality technological advancements ensuring timely diagnosis and treatment to lower the mortality rate,” said Dr Prathap Reddy, founder & chairman, Apollo Hospitals.
“This association with Datar Cancer Genetics has made a path-breaking achievement and at Apollo Cancer Centres, we are well equipped to diagnose breast cancers with the best-in-class advancements and treatments,” Reddy added.
“Unfortunately, most cancers are detected at advanced stages which necessitate more intensive and expensive treatments which have a greater risk of debilitating side effects and treatment failures. EasyCheck- Breast is the culmination of years of collaborative international research and innovation and has been developed, tested, and validated on population-sized cohorts,” said Rajan Datar, founder & chairman, Datar Cancer Genetics, said.
Breast cancer is the most common malignancy among women globally. It has now surpassed lung cancer as the leading cause of global cancer incidence in 2020, with an estimated 2.3 million new cases, representing 11.7% of all cancer cases. Epidemiological studies have shown that the global burden of Breast Cancer is expected to cross almost 2 million by the year 2030. As per data, in India, Breast Cancer accounted for 13.5% (178361) of all cancer cases and 10.6% (90408) of all deaths in 2020.
Credits – Source – https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/apollo-cancer-centres-launches-breast-cancer-detection-test-in-tie-up-with-datar-cancer-genetics/articleshow/92392084.cms